Eku Shimosegawa - Search Results

Year	Number of Results
2002	4
2004	4
2005	3
2006	5
2007	2
2008	7
2009	5
2010	7
2011	13
2012	15
2013	5
2014	7
2015	3
2016	7
2017	10
2018	10
2019	11
2020	11
2021	11
2022	9
2023	7
2024	1

1

Qualitative MR features to identify non-enhancing tumors within glioblastoma's T2-FLAIR hyperintense lesions.

Yamamoto S, Okita Y, Arita H, Sanada T, Sakai M, Arisawa A, Kagawa N, Shimosegawa E, Nakanishi K, Kinoshita M, Kishima H. Yamamoto S, et al. Among authors: shimosegawa e. J Neurooncol. 2023 Nov;165(2):251-259. doi: 10.1007/s11060-023-04454-9. Epub 2023 Nov 2. J Neurooncol. 2023. PMID: 37917281

2

Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with ⁸⁹Zr or ²¹¹At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.

Watabe T, Kabayama K, Naka S, Yamamoto R, Kaneda K, Serada S, Ooe K, Toyoshima A, Wang Y, Haba H, Kurimoto K, Kobayashi T, Shimosegawa E, Tomiyama N, Fukase K, Naka T. Watabe T, et al. Among authors: shimosegawa e. J Nucl Med. 2023 Dec 1;64(12):1949-1955. doi: 10.2967/jnumed.123.266313. J Nucl Med. 2023. PMID: 37827841 Free PMC article.

3

Cerebrospinal fluid amyloid beta with amyloid positron emission tomography concordance rates in a heterogeneous group of patients including late-onset psychotic disorders: a retrospective cross-sectional study.

Satake Y, Kanemoto H, Gotoh S, Akamine S, Suehiro T, Matsunaga K, Shimosegawa E, Yoshiyama K, Morihara T, Mori K, Ikeda M. Satake Y, et al. Among authors: shimosegawa e. Psychogeriatrics. 2023 Nov;23(6):1091-1093. doi: 10.1111/psyg.13024. Epub 2023 Sep 12. Psychogeriatrics. 2023. PMID: 37700563 No abstract available.

4

Evaluation of LAT1 Expression in Patients With Lung Cancer and Mediastinal Tumors: 18F-FBPA PET Study With Immunohistological Comparison.

Watabe T, Ose N, Naka S, Fukui E, Kimura T, Kanou T, Funaki S, Sasaki H, Kamiya T, Kurimoto K, Isohashi K, Tatsumi M, Shimosegawa E, Kato H, Ohgaki R, Kanai Y, Shintani Y. Watabe T, et al. Among authors: shimosegawa e. Clin Nucl Med. 2023 Oct 1;48(10):853-860. doi: 10.1097/RLU.0000000000004816. Epub 2023 Aug 30. Clin Nucl Med. 2023. PMID: 37682600

5

Evaluation of an Integrin α_vβ₃ Radiotracer, [¹⁸F]F-FPP-RGD₂, for Monitoring Pharmacological Effects of Integrin α_v siRNA in the NASH Liver.

Hiroyama S, Matsunaga K, Ito M, Iimori H, Morita I, Nakamura J, Shimosegawa E, Abe K. Hiroyama S, et al. Among authors: shimosegawa e. Nucl Med Mol Imaging. 2023 Aug;57(4):172-179. doi: 10.1007/s13139-023-00791-9. Epub 2023 Mar 7. Nucl Med Mol Imaging. 2023. PMID: 37483876

6

Characteristics of very late-onset schizophrenia-like psychosis classified with the biomarkers for Alzheimer's disease: a retrospective cross-sectional study.

Satake Y, Kanemoto H, Taomoto D, Suehiro T, Koizumi F, Sato S, Wada T, Matsunaga K, Shimosegawa E, Gotoh S, Mori K, Morihara T, Yoshiyama K, Ikeda M. Satake Y, et al. Among authors: shimosegawa e. Int Psychogeriatr. 2024 Jan;36(1):64-77. doi: 10.1017/S1041610222001132. Epub 2023 Jan 30. Int Psychogeriatr. 2024. PMID: 36714996

7

Effect of scan-time shortening on the ¹¹C-PHNO binding potential to dopamine D₃ receptor in humans and test-retest reliability.

Matsunaga K, Tonomura M, Abe K, Shimosegawa E. Matsunaga K, et al. Among authors: shimosegawa e. Ann Nucl Med. 2023 Apr;37(4):227-237. doi: 10.1007/s12149-022-01819-4. Epub 2023 Jan 19. Ann Nucl Med. 2023. PMID: 36656501 Free PMC article.

8

Characteristics of very late-onset schizophrenia-like psychosis as prodromal dementia with Lewy bodies: a cross-sectional study.

Kanemoto H, Satake Y, Suehiro T, Taomoto D, Koizumi F, Sato S, Wada T, Matsunaga K, Shimosegawa E, Hashimoto M, Yoshiyama K, Ikeda M. Kanemoto H, et al. Among authors: shimosegawa e. Alzheimers Res Ther. 2022 Sep 22;14(1):137. doi: 10.1186/s13195-022-01080-x. Alzheimers Res Ther. 2022. PMID: 36138485 Free PMC article.

9

Semiquantitative analysis using whole-body dynamic F-18 fluoro-2-deoxy-glucose-positron emission tomography to differentiate between benign and malignant lesions.

Watanabe M, Kato H, Katayama D, Soeda F, Matsunaga K, Watabe T, Tatsumi M, Shimosegawa E, Tomiyama N. Watanabe M, et al. Among authors: shimosegawa e. Ann Nucl Med. 2022 Nov;36(11):951-963. doi: 10.1007/s12149-022-01784-y. Epub 2022 Sep 3. Ann Nucl Med. 2022. PMID: 36057012

10

Comparison of the Therapeutic Effects of [²¹¹At]NaAt and [¹³¹I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model.

Watabe T, Liu Y, Kaneda-Nakashima K, Sato T, Shirakami Y, Ooe K, Toyoshima A, Shimosegawa E, Wang Y, Haba H, Nakano T, Shinohara A, Hatazawa J. Watabe T, et al. Among authors: shimosegawa e. Int J Mol Sci. 2022 Aug 21;23(16):9434. doi: 10.3390/ijms23169434. Int J Mol Sci. 2022. PMID: 36012698 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

136 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Results by year